Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FZ 010 is an oral capsule containing live, lyophilized therapeutic yeast developed by Fzata. It is designed to target interleukin-22 (IL-22) and modulate the gastrointestinal microbiome. The drug acts as a gastrointestinal microbiome modulator and interleukin-22 replacement, with its primary indications being diabetes mellitus and obesity. As of September 2024, it remains in preclinical development for these indications[2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FZ 010.